NAVIGATOR
2021
Tezepelumab in Severe, Uncontrolled Asthma
In 1,061 patients with severe uncontrolled asthma, tezepelumab 210 mg SC every 4 weeks reduced the annualised asthma exacerbation rate compared with placebo.
Result
Efficacy: Annualised asthma exacerbation rateRR 0.44 (95% CI 0.37-0.53)
Below 1 favours tezepelumab 210 mg SC every 4 weeks, above 1 favours placebo.
Event rates Tezepelumab 210 mg SC every 4 weeks 0.93 vs placebo 2.10 exacerbations/year
Also reported: Benefit preserved in eosinophils <300/µL (RR 0.59).
- Subtopic
- Anti-TSLP biologic
- Design
- Multicentre phase-3 RCT
- Relevance
- Important: one of several pillars.
- Source
- Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809.doi 10.1056/NEJMoa2034975
Discussion & critique
First biologic effective across all asthma phenotypes, including low-eosinophil disease; FDA-approved 2021.